Substitute Form PTO-1449 (Modified) FEB

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 16743-003001 / 12A-920716

Application No. 10/705,245

nf rmation Disclosure Statement by Applicant (Use several sheets if necessary)

**Applicant** 

Chen, et al.

Filing Date November 10, 2003 Group Art Unit Unknown

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,583,139	06/24/2003	Thorsett, et al.			
	AB						
	AC		·				
	AD						

	Foreig	n Patent Doc	uments or Pu	blished Foreign	Patent A	Application	ns	
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass		slation No
	AE							
	AF							
	AG							
	AH							

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
STK	AI	Bigby M, Jick S, Jick H, Amdt K. (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 256(24):3358-3363.
	AJ	Chan SH and Tan T. "HLA and allopurinol drug eruption" Dermatologica. 1989, 179(1):32-3.
	AK	Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. <i>Postgrad Med J.</i> 1999, 75(889):680-1.
	AL	Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia. Curr Opin Rheumatol. 2001, 13(4):285-90.
	' AM	Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 1991, 91(6):631-4.
	AN	Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. <i>Biochem Pharmacol</i> .1995, 50(9):1353-9.
	AO	Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, Kappeler A, von Greyerz S, Braathen LR, Pichler WJ. T cell involvement in cutaneous drug eruptions. <i>Clin Exp Allergy</i> . 2001, 31(9):1398-408.
	AP	Khan MA. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol. 2000;12(4):235-8.
V	AQ	Lazarou J, Pomeranz BH, Corey PN. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279(15):1200-1205.

Examiner Signature /Stephen Kapushoc/	Date Considered 05/10/2006
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

Spassare Form PTO-1449
(Modfæd)

FEB 8 4 2804 Linformati n

U.S. Department of Commerce Patent and Trademark Office Attomey's Docket No. 16743-003001 / 12A-920716 Application No. 10/705,245

by Applicant
(Use several sheets if necessary)

Applicant

Chen, et al.

Group Art Unit

Filing Date

November 10, 2003

Unknown

		November 10, 2003	<u>Unknown</u>					
	Other D	Documents (include Author, Title, Date, and Plac	e of Publication)					
Examiner	Desig.							
Initial	ID	Document						
STK	AR	Leeder JS. Mechanisms of idiosyncratic hypersensitivity reaction 1998, 39 Suppl 7:S8-16.						
	AS	Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick Park BK. Hypersensitivity reactions to carbamazepine: characte phenotype, and cytokine profile of drug-specific T cell clones. M	rization of the specificity,					
	AT	Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellwe production by human drug-specific T cell clones. Int Arch Allerg 80.	Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol. 1997, 113(1-3):177-					
	AU	Pirmohamed M, Lin K, Chadwick D, Park BK. TNFα promoter carbamazepine-hypersensitive patients. Neurology. 2001, 56(7):	Pirmohamed M, Lin K, Chadwick D, Park BK. TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology, 2001, 56(7):890-6					
	AV	Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs. <i>Tissue Antigens</i> . 1986, 28(4):251-4.						
	AW	Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. <i>Arch Dermatol.</i> 1987, 123(9):1171-3.						
	AX	Roujeau JC. The spectrum of Stevens-Johnson syndrome and too classification. <i>J Invest Dermatol.</i> 1994, 102(6):28S-30S.						
	AY	Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994, 331(19):1272-85.						
	AZ	Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995, 333(24):1600-7.						
	AAA	Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson synd treatment. <i>Arch Ophthalmol</i> . 1997, 115(4):550-3.	·					
	ABB	Svensson CK, Cowen EW, Gaspari, AA. (2000) Cutaneous drug 53(3):357-379.						
	ACC	Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, I slow acetylator genotype is a risk factor for sulphonamide-induce Stevens-Johnson syndrome. <i>Pharmacogenetics</i> . 1995, 5(4):255-8	d toxic epidermal necrolysis and					
V	ADD	Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, P Molecular diagnosis of thiopurine S-methyltransferase deficiency and mercaptopurine intolerance. <i>Ann Intern Med.</i> 1997, 126(8):6	: genetic basis for azathioprine					

Examiner Signature	/Stephen Kapushoc/	Date Considered	05/10/2006
EXAMINER: Initials cit	ation considered. Draw line through citation if n	ot in conformance and	not considered. Include copy of this form with

Substitute 9 (Modified)

om PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 16743-003001 / 12A-920716

**Applicant** 

Application No.

Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary)

Chen, et al.

(37 CFR §1.98(b))

Filing Date November 10, 2003 **Group Art Unit** 1614

10/705,245

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

	Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	slation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
	AD								
	AE								
	AF								

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
STK	AG	Chung, W.H., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486.
	АН	Gumperz, J.E., et al. (1995). The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 181(3):1133-1144.
	AI	Gut, J. (2002). Severe adverse drug reactions and theragenomics. Business Briefing Pharmatech. Retrieved from the Internet: <u>URL: http://therastrat.com/downloads/Gut_2002_Servere_Adverse_Drug_Reactions.pdf</u> > retrieved on 2004-10-01.
	AJ	Hildesheim, A., et al. (2002). Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 94(23):1780-1789.
	AK	Mallal, S. et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359(9308):727-732.
	AL	Nassif, A., et al. (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 118(4):728-733.
	AM	Pirmohamed, M., and Park, B.K. (2003). Adverse drug reactions: back to the future. Br J Clin Pharmacol. 55(5):486-492.
	AN	Romphruk, A., et al. (2003). HLA-B*15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet. 30(2):153-158.

Examiner Signature /Stephen Kapushoc/	Date Considered 05/10/2006
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with